ThermoGenesis Extends Global Reach for Bone Marrow Products With New Distribution Agreements

RANCHO CORDOVA, Calif., April 26 /PRNewswire-FirstCall/ -- ThermoGenesis Corp. (Nasdaq: KOOL), a leading supplier of innovative products for processing and storing adult stem cells, announced today that it has signed two new distribution agreements that will further extend its global reach into Asia and Central and South America for its offerings in the bone marrow stem cell regenerative medicine market. The Company has now completed four new distribution agreements in the past 90 days, significantly enhancing its ability to market and sell its products throughout the world.

The first agreement is for the exclusive distribution of the Company's devices used in the process of stem cells from bone marrow, the MXP™ MarrowXpress™ and the Res-Q™60 BMC (Res-Q) Systems, covering India, Malaysia and Thailand. This agreement is with TotipotentSC, a distribution company with locations in the U.S. and India.  The term of this agreement is three-years.

ThermoGenesis also announced the amendment of an exclusive distribution agreement with Comercio Exportacai e Importacao de Materiais Medicos Ltda. (CEI) to include the rights to market and distribute the Res-Q and MXP Systems in Mexico and Central and South American countries, including Brazil, Chile, Columbia, Costa Rica, Panama, Peru, Uruguay and Venezuela. The contract runs through May 2011.

"We are delighted to be working with these firms. Their addition to our marketing and distribution efforts provide ThermoGenesis with an enhanced presence in the growing worldwide regenerative medicine market. As a result of these agreements, and those completed over the past three months, we now have extensive coverage for our core offerings in major geographies throughout the world including our presence in the growing Asian market. Furthermore, we anticipate adding additional distributor relationships in the near-term," said J. Melville Engle, Chief Executive Officer of ThermoGenesis.

In late January, ThermoGenesis completed an enhanced distribution agreement with GE Healthcare for the AutoXpress AXP® System, excluding certain countries in Central and South America, Asia, CIS and Eastern Europe. In March, ThermoGenesis announced an agreement with Fenwal, Inc., to exclusively market and distribute the AXP and BioArchive® Systems for use in cord blood processing and storage in China, India and Japan.  

"Establishing these types of relationships with leading distributors is an integral element of our strategy to achieve leadership in the adult stem cell processing and storage markets. It demonstrates the momentum we are building at the Company, while providing strong validation of our products and scientific innovation," Engle noted.

Located in the U.S. and India, TotipotentSC provides products and services specifically targeted to the regenerative medicine market. TotipotentSC was the first stem cell device and consulting company to establish a presence in India and now operates two facilities in the country, and has scientific advisors, including clinicians from the Albert Einstein College of Medicine, and the University of Texas MD Anderson Cancer Center.

CEI is a leader in its field and has more than 35 years experience in sales, marketing and manufacturing of medical devices, providing quality products and services throughout Latin America.

About ThermoGenesis Corp.

ThermoGenesis Corp. (www.thermogenesis.com) is a leader in developing and manufacturing automated blood processing systems and disposable products that enable the manufacture, preservation and delivery of cell and tissue therapy products. These products include:

• The BioArchive® System, an automated cryogenic device, is used by cord blood stem cell banks in more than 30 countries for cryopreserving and archiving cord blood stem cell units for transplant.
• AXP® AutoXpress™ Platform (AXP), a proprietary family of automated devices that includes the AXP and the MXP™ MarrowXpress™ and companion sterile blood processing disposables for harvesting stem cells in closed systems. The AXP device is used for the processing of cord blood. The MXP is used for the preparation of cell concentrates, including stem cells, from bone marrow aspirates in the laboratory setting.
• The Res-Q™ 60 BMC (Res-Q), a point-of-care system that is designed for the preparation of cell concentrates, including stem cells, from bone marrow aspirates.
• The CryoSeal® FS System, an automated device and companion sterile blood processing disposable, is used to prepare fibrin sealants from plasma in about an hour. The CryoSeal FS System is approved in the U.S. for liver resection surgeries. The CryoSeal FS System has received the CE-Mark which allows sales of the product throughout the European community.

This press release contains forward-looking statements, and such statements involve risks and uncertainties that could cause actual outcomes to differ materially from those contemplated by the forward-looking statements. Several factors, including timing of FDA approvals, changes in customer forecasts, our failure to meet customers' purchase order and quality requirements, supply shortages, production delays, changes in the markets for customers' products, introduction timing and acceptance of our new products scheduled for fiscal year 2010, and introduction of competitive products and other factors beyond our control, could result in a materially different revenue or profitability outcome and/or in our failure to achieve the revenue levels we expect for fiscal 2010. A more complete description of these and other risks that could cause actual events to differ from the outcomes predicted by our forward-looking statements is set forth under the caption "Risk Factors" in our annual report on Form 10-K and other reports we file with the Securities and Exchange Commission from time to time, and you should consider each of those factors when evaluating the forward-looking statements.

SOURCE ThermoGenesis Corp.